Get the Stockscreener App
9.89
11.62%
-1.30
Pre-market:
9.87
-0.02
-0.20%
Passage Bio Inc stock is traded at $9.89, with a volume of 46,502.
It is down -11.62% in the last 24 hours and up +16.22% over the past month.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
See More
Previous Close:
$11.19
Open:
$11.19
24h Volume:
46,502
Relative Volume:
0.90
Market Cap:
$31.73M
Revenue:
-
Net Income/Loss:
$-45.52M
P/E Ratio:
-1.0168
EPS:
-9.7265
Net Cash Flow:
$-31.51M
1W Performance:
+22.40%
1M Performance:
+16.22%
6M Performance:
+16.75%
1Y Performance:
+2,633%
1-Day Range:
$9.50
$11.20
1-Week Range:
$7.55
$11.30
52-Week Range:
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
9.89 | 31.73M | 0 | -45.52M | -31.51M | -9.7265 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Initiated | Oppenheimer | Outperform |
| Feb-10-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Short Squeeze: What is the earnings history of Passage Bio IncTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PASG PE Ratio & Valuation, Is PASG Overvalued - Intellectia AI
Passage Bio (PASG) 2026 proxy details director elections, KPMG ratification and executive pay - Stock Titan
Passage Bio advances frontotemporal dementia trial and reports 2025 results - MSN
Stock List: Research Stocks from Around the World - GuruFocus
BOLD PE Ratio & Valuation, Is BOLD Overvalued - Intellectia AI
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026 - EIN News
Passage Bio Inc Stock: Gene Therapy Pioneer Faces Clinical and Funding Hurdles in Biotech Arena - AD HOC NEWS
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Bond Watch: Can Passage Bio Inc reach all time highs this year2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Oppenheimer Initiates Coverage on PASG with Outperform Rating | - GuruFocus
Oppenheimer Initiates Passage Bio at Outperform - Moomoo
Baird initiates Passage Bio stock coverage with outperform rating By Investing.com - Investing.com India
Baird initiates Passage Bio stock coverage with outperform rating - Investing.com
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS
Oppenheimer initiates Passage Bio stock with outperform rating - Investing.com UK
Oppenheimer initiates Passage Bio stock with outperform rating By Investing.com - za.investing.com
Passage Bio, Inc. (NASDAQ:PASG) Receives $28.00 Average Price Target from Brokerages - Defense World
Passage Bio Inc Stock: Gene Therapy Innovator Focused on Rare Neurological Disorders Amid Biotech Vo - AD HOC NEWS
Passage Bio (PASG) price target increased by 21.85% to 40.39 - MSN
Options Flow: Can Sprout Social Inc sustain earnings growth2026 Institutional & Community Verified Watchlist Alerts - baoquankhu1.vn
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors - The Manila Times
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Passage BIO (PASG) CFO receives stock option grant for 15,610 shares - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
PASG Surges 13% on Thin Volume — But No Catalyst to Back It - Bitget
Buybacks Report: Can Passage Bio Inc stock outperform in a bear market2026 Setups & Reliable Breakout Forecasts - baoquankhu1.vn
Passage Bio Inc Stock (ISIN: US70267E1055) Faces Biotech Headwinds Amid Analyst Optimism and Funding - AD HOC NEWS
Can Passage Bio Inc stock outperform in a bear market2026 Buyback Activity & Daily Entry Point Alerts - baoquankhu1.vn
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway - The Globe and Mail
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results - MyChesCo
Weekly Trades: Is DISTW stock a hidden gemMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Lowered to Sell Rating by Wall Street Zen - Defense World
Will SBLK stock keep outperforming rivalsPortfolio Value Summary & AI Driven Price Forecasts - Naître et grandir
Portfolio Shifts: Does PRLD have declining or rising EPSTrade Signal Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trade Report: What insider trading reveals about Passage Bio Inc. stockPortfolio Profit Report & Precise Entry and Exit Recommendations - Naître et grandir
Passage Bio (PASG) Gets a Buy from Chardan Capital - The Globe and Mail
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Passage BIO 10-K: Net loss $45.5M; EPS $(14.35) - TradingView
PASG: Net loss narrowed to $45.5M in 2025 as PBFT02 advanced and cash runway extended to Q1 2027 - TradingView
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):